Business Services Industry
SurgiLight Concludes the Joint Venture with MicraUSA, Inc. in the United Kingdom
Business Wire, July 18, 2000
Business Editors/Health, Medical & Technology Writers
ORLANDO, Fla.--(BUSINESS WIRE)--July 18, 2000
SurgiLight Inc., (OTCBB:SRGL) announced today that it has concluded a Joint Venture Agreement with MicraUSA, Inc. to assemble the MicraLight Escan 2020 scanning laser, designed for vision correction, in the United Kingdom and to market the system throughout the world.
- Most Popular Articles in Business
- Research and Markets : Tesco Plc - SWOT Framework Analysis
- Do Us a Flavor - Ben & Jerry's Issues a Call for Euphoric New Flavors
- eBay made easy: ready to start an eBay business? These 5 simple steps will ...
- Katrina's lawsuit surge: a legal battle to force insurers to pay for flood ...
- Wal-Mart's newest distribution center opened last month near the southwest ...
- More »
MicraUK, Ltd., is a wholly owned subsidiary of MicraUSA, Utica, New York and gained ISO 9002 and EN 46002 certification for its quality manufacturing and engineering system in 1995 and it is fully accredited for European CE marking. It was founded over twenty-five years ago and is thought to be one of the premier custom Ophthalmic instrument manufacturing companies in the world and custom designs, and manufactures instruments for companies like Bausch & Lomb (NYSE:BOL), Pharmacia & Upjohn (NYSE:PNU), Alcon, and Codman (a Johnson and Johnson company) as well as international companies like Corneal (France) and Tomey (Japan).
J.T. Lin, Ph.D., President and CEO commented, "We are extremely anxious to begin the assembly of the MicraLight Escan 2020 scanning laser system in the Untied Kingdom. This Joint Venture should enhance our sales in countries that require the CE mark outside the United States and create opportunities that were not available to us before this Agreement. The MicraLight Escan 2020 is an economical, state-of-the-art scanning laser designed to perform LASIK procedures and will be marketed throughout the world, outside the United States."
"We are very excited about the potential of this Joint Venture", stated Timothy J. Shea, Senior Vice President and COO of the Company. "This Agreement affords us the opportunity to assemble the Escan 2020 in a certified quality environment and will assist us as we continue to grow our Company and improve our own quality system."
The Company is currently negotiating an Agreement to begin clinical trials with the IR-3000 laser for presbyopia procedures in Japan and expects to begin these trials within the next few weeks. The Company is also shipping the EX-308 laser to Duke University Medical Center within the next few weeks to continue the treatment psoriasis and to explore new and exciting applications with this product. The Company expects to receive FDA clearance for the treatment of psoriasis with the EX-308 shortly.
The Company is also negotiating a number of new international Laser Eye Center (LEC) contracts in Asia, Latin America and expects to conclude another LEC contract in Vietnam shortly. The Company has also received a deposit from Diagnostic Instrument Group (DIG), its Latin American distributor for the UV-195 for LASIK procedures and intends to become very aggressive in Latin America.
SurgiLight is a world leader in the development of new infrared technologies, a pioneer and inventor of scanning lasers and lasers for presbyopia reversal with four patents submitted in US. The Company continues to receive royalty income from international eye laser and cosmetic centers. For more detail information, please visit the Company's wet site at www.surgilight.com.
This press release may contain forward-looking statements regarding future events and performance of the Company, which involves risks and uncertainties that could materially affect actual results. Investors should refer to documents that the Company files with the SEC for a description of certain factors that could cause actual results to vary from current expectations and the forward-looking statements contained in this press release.
COPYRIGHT 2000 Business Wire
COPYRIGHT 2000 Gale Group